Compare Williams Companies Inc (WMB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Williams Companies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Williams Companies Inc trades at $73.75 (market cap $88.45B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Williams Companies Inc pays a 2.9% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Williams Companies Inc nearer its low. Which is the better fit depends on your goals.
| WMB | XBI | |
|---|---|---|
Market Cap | $88.45B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $79.40 | $164.28 |
52-Week Low | $56.51 | $86.92 |
Enterprise Value | $119.07B | — |
Dividend Yield | 2.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Williams Companies (WMB) trades at $73.60, up 2.44% with a bullish technical signal despite mixed earnings history. The company reported strong Q1 2026 results but missed Q2 estimates, while raising full-year EBITDA guidance to $8.4 billion. Analyst consensus remains strongly bullish with a $87.14 price target, supported by the recent $5.5 billion Momentum Midstream acquisition that enhances Gulf Coast exposure and supports 11% annual growth targets through 2030.
WMB presents a compelling investment case with strong profitability metrics (25.18% net margin, 24.02% ROE) and dividend stability ($2.10 annualized). Key risks include execution challenges from the Momentum integration, debt levels at 52.07% of assets, and potential volatility from energy market fluctuations. The stock offers 18% upside to consensus target with institutional support despite recent position reductions.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
